Cited by 284Pharmaceutical Economics and PolicyPharmaceutical industry and healthcareAlzheimer's disease research and treatments

The DOI matches its Crossref record.

Is Pharma Running Out of Brainy Ideas?

Miller, Greg·2010·Science

DOI 10.1126/science.329.5991.502

Open this paper in CoChat — free account

Abstract

Recent cutbacks raise concerns about the future of drug development for nervous system disorders.

Integrity signals

Registry

Crossref · 10.1126/science.329.5991.502

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 283

The Infernal Alternatives of Corporate Pharmaceutical Research: Abandoning Psychiatry
Dumit, J. (2017) · Medical Anthropology · doi:10.1080/01459740.2017.1360877 · Cited by 46
“…disorders as safer bets,” says Steven Paul, who stepped down in February as executive vice president for science and technology for Eli Lilly and Co. “Their perception is that the science is a little richer and the odds are less daunting in some of these other areas,” he says (Miller 2010:502).”
BackgroundInfluential
Animal Paradigms to Assess Cognition with Translation to Humans
Wallace, T. L., Ballard, T. M., & Glavis-Bloom, C. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-16522-6_2 · Cited by 26
What the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25
Something's got to give: psychiatric disease on the rise and novel drug development on the decline
Chandler, D. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.08.003 · Cited by 25
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study
Bloomfield, M., Yamamori, Y., Hindocha, C., Jones, A., Yim, J. L., Walker, H. R., Statton, B. K., Wall, M. B., Lees, R., Howes, O. D., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06070-3 · Cited by 30
“2011)), and major cutbacks in psychiatric drug development (Abbott 2011; Miller 2010).”
Psychedelic innovations and the crisis of psychopharmacology
Langlitz, N. (2022) · BioSocieties · doi:10.1057/s41292-022-00294-4 · Cited by 24
“Former NIMH director Hyman (2013) hoped that advances in psychiatric genetics would facilitate the development of new drugs.”
Influential
Personalized Medicine in ADHD and Depression: Use of Pharmaco-EEG
Arns, M., & Olbrich, S. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_295 · Cited by 25
“Furthermore, several large pharmaceutical companies announced that they would ‘…pull the plug on drug discovery in some areas of neuroscience…’ (Miller 2010).”
Background
The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia
Ashton, M. M., Dean, O. M., Walker, A. J., Bortolasci, C. C., Ng, C. H., Hopwood, M., Harvey, B. H., Möller, M., McGrath, J. J., Marx, W., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00115 · Cited by 25
“pharmaceutical companies, is dwindling (5, 6); as such, the investigation of novel therapeutics is both warranted, and needed.”
Background
From genes to therapeutic targets for psychiatric disorders – what to expect?
Muglia, P. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.08.003 · Cited by 23
In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells
Korecka, J. A., Levy, S. A., & Ole Isacson, A. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.12.004 · Cited by 24
“does not translate to a positive outcome in clinical application (Geerts, 2009; Henderson et al., 2013; Hyman, 2013; Miller, 2010).”
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models
Kelly, J., Boyle, N. T., Cole, N., Slator, G. R., Colivicchi, M. A., Stefanini, C., Gobbo, O. L., Scalabrino, G., Ryan, S. M., Elamin, M., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.09.024 · Cited by 23
Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.
MacEwan, J. P., Seabury, S. A., Aigbogun, M. S., Kamat, S., van Eijndhoven, E. A., François, C., Henderson, C., & Citrome, L. (2016) · PubMed Central · Cited by 23
The Emerging Use of Brain Stimulation Treatments for Psychiatric Disorders
Fitzgerald, P. B. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.615294 · Cited by 23
True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence
Goetghebeur, P., & Swartz, J. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645269 · Cited by 22
“A spate of recent costly unsuccessful development pathways in central nervous system (CNS) indications, including Alzheimer’s disease and schizophrenia, have resulted in smaller companies leaving this therapeutic area, while many larger ones have dramatically downscaled their CNS development programmes or pulled out o…”
Background
BioBanking as the central tool for translational medicine CTM issue 2013
Marko‐Varga, G. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-4 · Cited by 20
“Biobanks of human patient samples tissues and blood fractions are increasingly recognized as major assets in disease research [9,10].”
Background
Depression: An Insight into Heterocyclic and Cyclic Hydrocarbon Compounds Inspired from Natural Sources
Shah, A. J., Mir, R. H., Mohi-ud-din, R., Pottoo, F. H., Masoodi, M. H., & Bhat, Z. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210426115234 · Cited by 21
“Thus it becomes imperative to look for novel therapies based on natural products [14].”
Background
Neuroscience and Critique
Vos, J. D., & Pluth, E. (2015) · Routledge eBooks · doi:10.4324/9781315714189 · Cited by 85
Human iPSC-Derived Neurons with Reliable Synapses and Large Presynaptic Action Potentials
Bullmann, T., Kaas, T., Ritzau‐Jost, A., Whner, A., Kirmann, T., Rizalar, F. S., Holzer, M., Nerlich, J., Puchkov, D., Geis, C., et al. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.0971-23.2024 · Cited by 22
Know Thyself: Well-Being and Subjective Experience.
LeDoux, J. E., Brown, R., Pine, D. S., & Hofmann, S. G. (2018) · Europe PMC (PubMed Central) · Cited by 22
Disease-directed engineering for physiology-driven treatment interventions in neurological disorders
Wood, T. R., & Nance, E. A. (2019) · APL Bioengineering · doi:10.1063/1.5117299 · Cited by 21
Importance and hurdles to drug discovery for neurological disease
Berger, J. R., Choi, D. W., Kaminski, H. J., Gordon, M. F., Hurko, O., D’Cruz, O., Pleasure, S. J., & Feldman, E. L. (2013) · Annals of Neurology · doi:10.1002/ana.23997 · Cited by 19
Framework for Multistakeholder Patient Registries in the Field of Rare Diseases
Schoenmakers, D. H., van den Berg, S., Timmers, L., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209743 · Cited by 18
“In fact, orphan drugs for RND and inborn errors of metabolism dominate nononcological orphan drugs in both the United 2-4 and the European Union 5 New therapies such as gene therapy are promising but also pose new academic, regulatory, and ﬁ nancial challenges These challenges include lack of evidence on (long-term) s…”
Background
Back to the future of psychopharmacology: A perspective on animal models in drug discovery
Hendriksen, H., & Groenink, L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.020 · Cited by 18
“Now that large pharmaceutical companies restrict their CNS drug development because of the low chance of success (Miller, 2010), maybe academia can be the throttle letting the drug pipeline roar again.”
Background
Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial
Abram, S. V., Coster, L. D., Roach, B. J., Mueller, B. A., van Erp, T. G. M., Calhoun, V. D., Preda, A., Lim, K. O., Turner, J. A., Ford, J. M., et al. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz091 · Cited by 18
Biomarkers in mood disorders research: developing new and improved therapeutics
Niciu, M. J., Mathews, D. C., Ionescu, D. F., Richards, E. M., Furey, M. L., Yuan, P., Nugent, A. C., Henter, I. D., Machado‐Vieira, R., & Zarate, C. A. (2014) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000027 · Cited by 18
Engineering microsystems to recapitulate brain physiology on a chip
Ndyabawe, K., & Kisaalita, W. S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.008 · Cited by 17
Neuroplasticity and the brain connectome: what can Jean Talairach’s reflections bring to modern psychosurgery?
Bourdillon, P., Apra, C., Lévêque, M., & Vinckier, F. (2017) · Neurosurgical FOCUS · doi:10.3171/2017.6.focus17251 · Cited by 16
Neuroimaging Insights: Kava’s (Piper methysticum) Effect on Dorsal Anterior Cingulate Cortex GABA in Generalized Anxiety Disorder
Savage, K. M., Sarris, J. J., Hughes, M. E., Bousman, C., Rossell, S. L., Scholey, A. B., Stough, C. K. K., & Suo, C. (2023) · Nutrients · doi:10.3390/nu15214586 · Cited by 18
Validation of experimental medicine methods in psychiatry: The P1vital approach and experience
Dawson, G. R., Craig, K. J., & Dourish, C. T. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.013 · Cited by 16
“In March 2007 P1vital entered into a consortium agreement with AstraZeneca, GlaxoSmithKline, Lundbeck, Organon and Wyeth to fund a series of studies over a period of three years to establish the sensitivity of healthy volunteer CNS experimental medicine models and to validate their ability to detect the efficacy of no…”
BackgroundInfluential
High-content analysis and Kinetic Image Cytometry identify toxicity and epigenetic effects of HIV antiretrovirals on human iPSC-neurons and primary neural precursor cells
Smith, A. S., Ankam, S., Farhy, C., Fiengo, L., Basa, R. C. B., Gordon, K. L., Martin, C. T., Terskikh, A. V., Jordan‐Sciutto, K. L., Price, J. H., et al. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107157 · Cited by 18
Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness
Johnsen, E., & Kroken, R. A. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312462275 · Cited by 20
“For several reasons there has been paucity in the development of molecules with novel mechanisms of action for bipolar mania and schizophrenia reaching clinical practice [Miller, 2010; Williams, 2011].”
Background
Optogenetics in preclinical neuroscience and psychiatry research: recent insights and potential applications
Britt, J. P., McDevitt, R. A., & Reed, S. J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s45896 · Cited by 17
“8 To reinvigorate research, it may be necessary to take a more refined technological approach to the study of disease symptoms and treatment.”
Mental health burden and unmet needs for treatment: a call for justice
Dakić, T. (2019) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.254 · Cited by 16
Preserving and enhancing mitochondrial function after stroke to protect and repair the neurovascular unit: novel opportunities for nanoparticle-based drug delivery
Novorolsky, R. J., Kasheke, G. D. S., Hakim, A. M., Földvári, M., Dorighello, G. G., Sekler, I., Vuligonda, V., Sanders, M. E., Renden, R., Wilson, J. J., et al. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1226630 · Cited by 18
“Most putative neuroprotective and restorative drugs fail in the clinic because of lack of efficacy (Cheng et al., 2004; Miller, 2010; Choi et al., 2014).”
Background
What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?
Becker, R. E., Seeman, M. V., Greig, N. H., & Lahiri, D. K. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00214-x · Cited by 15
Collaboration Versus Outsourcing: The Need to Think Outside the Box
Robertson, G. M., & Mayr, L. M. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.160 · Cited by 15
Impact of human CA8 on thermal antinociception in relation to morphine equivalence in mice
Fu, E. S., Erasso, D. M., Zhuang, G. Z., Upadhyay, U., Ozdemir, M., Wiltshire, T., Sarantopoulos, K. D., Smith, S. B., Maixner, W. D., Martin, E. R., et al. (2017) · Neuroreport · doi:10.1097/wnr.0000000000000872 · Cited by 14
Perspectives on the current developments with neuromodulation for the treatment of epilepsy
Kwon, C., Jetté, N., & Ghatan, S. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1700795 · Cited by 14
Short-circuiting biology: Digital phenotypes, digital biomarkers, and shifting gazes in psychiatry
Mulinari, S. (2023) · Big Data & Society · doi:10.1177/20539517221145680 · Cited by 13
“Top-ranking researchers (Agid et al., 2007) and pharmaceutical executives (Miller, 2010) have openly pondered the causes of and solutions to the lack of progress in diagnosing, explaining, and treating mental illness.”
Background
The making of a mushroom people: Toward a moral anthropology of psychedelics beyond hype and anti‐hype
Langlitz, N. (2023) · Anthropology Today · doi:10.1111/1467-8322.12813 · Cited by 14
Alzheimer’s Disease Clinical Trials: Changing the Paradigm
Cummings, J. L. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0234-y · Cited by 12
“There is concern that continued failures in clinical trials will lead the pharmaceutical industry to redirect resources away from AD drug development, as has already happened in the field of schizophrenia [4].”
Background
Inhibition of the glucocorticoid synthesis reverses stress-induced decrease in rat's 50-kHz ultrasonic vocalizations
Popik, P., Kos, T., Pluta, H., Nikiforuk, A., Rojek-Sito, K., & Ryguła, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.11.029 · Cited by 14
Human-Monkey Chimeras for Modeling Human Disease: Opportunities and Challenges
Angeles, A. D. L., Hyun, I., Latham, S. R., Elsworth, J. D., & Redmond, D. E. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9524-0_15 · Cited by 12
Human–Monkey Chimeras for Modeling Human Disease: Opportunities and Challenges
Angeles, A. D. L., Hyun, I., Latham, S. R., Elsworth, J. D., & Redmond, D. E. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0162 · Cited by 13
Nonpublication of trial results for new neurological drugs: A systematic review
Hakala, A., Fergusson, D. A., & Kimmelman, J. (2017) · Annals of Neurology · doi:10.1002/ana.24952 · Cited by 11
‘The Explanation You Have Been Looking For’: Neurobiology as Promise and Hermeneutic Closure
Davis, J. E. (2021) · Culture Medicine and Psychiatry · doi:10.1007/s11013-021-09737-2 · Cited by 11
“Yet, none of this research has actually translated into routine clinical interventions (Ross, Travis, and Arbuckle 2015) and pharmaceutical companies have cut back sharply on psychiatric drug research (Miller 2010).”
Background
Special issue on CNS experimental medicine
Dawson, G. R., Dourish, C. T., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111415342 · Cited by 11
“Nowhere has this been more profoundly experienced than in psychiatry where two large Pharma companies, GlaxoSmithKline and AstraZeneca, recently announced the closure of their discovery research divisions (Miller, 2010).”
Brain-Wide Transgene Expression in Mice by Systemic Injection of Genetically Engineered Exosomes: CAP-Exosomes
Sarkar, S. N., Corbin, D. R., & Simpkins, J. W. (2024) · Pharmaceuticals · doi:10.3390/ph17030270 · Cited by 10
“Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging [2,3].”
Background
Evidence‐Based Medicine in Health Care Reform
Hughes, G. B. (2011) · Otolaryngology · doi:10.1177/0194599811419458 · Cited by 10
The use of probiotics in depression
Lange, K. W., Nakamura, Y. K., & Lange, K. M. (2020) · Journal of Food Bioactives · doi:10.31665/jfb.2020.12244 · Cited by 9
“The need for the development of novel pharmacological compounds for depression has repeatedly been emphasized (e.g. Insel, 2015; Miller, 2010), and additional approaches in the prevention and treatment of depression are required.”
Background
Debunking the ethical neuroenhancement debate
Schleim, S., & Quednow, B. B. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780198727392.003.0010 · Cited by 10
Repairing blood-CNS barriers: Future therapeutic approaches for neuropsychiatric disorders
Bicker, J., Alves, G., Fonseca, C., Falcão, A. C., & Fortuna, A. C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105226 · Cited by 9
High-Throughput Phenotypic Assay for Compounds That Influence Mitochondrial Health Using iPSC-Derived Human Neurons
MacMullen, C., & Davis, R. L. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211000671 · Cited by 9
“This i3Neuron mitochondrial phenotypic assay offers many advantages: (1) It is performed using a homogeneous population of the target cells of interest.”
Method
Computational Modeling of Multi-target-Directed Inhibitors Against Alzheimer’s Disease
Kumar, A., & Sharma, A. K. (2017) · Neuromethods · doi:10.1007/978-1-4939-7404-7_19 · Cited by 10
Are omega-3 fatty acids efficacious in the treatment of depression? A review
Lange, K. W., Nakamura, Y., Zhao, H., Bai, D., & Wang, H. (2021) · Journal of Food Bioactives · doi:10.31665/jfb.2021.14265 · Cited by 9
“The need for the development of further medications for the treatment of depression has repeatedly been emphasized (Insel, 2015; Miller, 2010), as has the need for novel approaches to the prevention and therapy of depression.”
Background
The Misunderstood Higher-Order Approach to ConsciousnessPreprint
Brown, R., Lau, H. C., & LeDoux, J. E. (2019) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/xpy8h · Cited by 9
The Birth of the Psychedelic Industry: Capitalising on the Psychedelic Renaissance
Yoo, M., & Sakopoulos, S. (2024) · Future Humanities · doi:10.1002/fhu2.70004 · Cited by 9
“Enthusiasts argue that these new drugs can serve as ‘ magic bullets ’ for mental health to break-through the ongoing crisis in biopsychiatry and as symbols of enhanced lifestyles (Langlitz 2022; Miller 2010).”
Zwischen Psyche und Gehirn
Fuchs, T. A. E. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0317-z · Cited by 8
“Hier verweist man allerdings inzwischen meist auf die Tiefenhirn- oder Magnetstimulation, denn die pharmazeutische Industrie hat sich angesichts geringer Erfolgschancen bereits zu einem Großteil aus der Forschung zurückgezogen [1, 51], und auch die viel beschworene „maßgeschneiderte“, „personalisierte Psychiatrie“ auf…”
Background
Heart Rate Variability as a Translational Biomarker for Emotional and Cognitive Deficits
Ellenbroek, B. A., Kidwell, M., Colussi‐Mas, J., & Youn, J. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00013-8 · Cited by 7
Drug repurposing and beyond: the fundamental role of pharmacology
Amantea, D. (2015) · Functional Neurology · doi:10.11138/fneur/2015.30.1.079 · Cited by 7
“Most failures in the drug development pipeline are due to inadequate efficacy or to a lack of safety emerging in phase III clinical trials or after drug approval (Miller, 2010).”
Background
Returning to basic principles to develop more effective treatments for central nervous system disorders
Wexler, B. E. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221078291 · Cited by 6
“Ashby’s Homeostats demonstrated general principles relevant to living things and the brain: (1) “In a large polystable system the whole reaction will be based on activations that are both numerous and widely scattered .”
Background
Modulating brain integrative actions as a new perspective on pharmacological approaches to neuropsychiatric diseases
Marcoli, M., Agnati, L. F., Franco, R., Cortelli, P., Anderlini, D., Guidolin, D., Cervetto, C., & Maura, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1038874 · Cited by 7
Nanoparticulate systems as drug carriers: the need
Patravale, V. B., Dandekar, P. P., & Jain, R. D. (2012) · Elsevier eBooks · doi:10.1533/9781908818195.1 · Cited by 8
“Other properties of nanoparticles, like biodegradability, low particle size (≈ 100 nm), prolonged circulation by surface modifi cation, receptor medicated transcytosis, large-scale production ability, possibility for loading of drugs/peptides and the ability to control the release of encapsulated active agent, make th…”
Background
Understanding madness?
Frith, C. (2015) · Brain · doi:10.1093/brain/awv373 · Cited by 7
Defined Differentiation of Human Pluripotent Stem Cells to Brain Microvascular Endothelial-Like Cells for Modeling the Blood-Brain Barrier
Foreman, K. L., Shusta, E. V., & Palecek, S. P. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3287-1_10 · Cited by 5
Transcriptional Responses of In Vitro Blood–Brain Barrier Models to Shear Stress
Foreman, K. L., Gastfriend, B. D., Katt, M. E., Palecek, S. P., & Shusta, E. V. (2025) · Biomolecules · doi:10.3390/biom15020193 · Cited by 7
“Despite the prevalence of central nervous system (CNS) diseases, new therapeutic treatments are approved at a much lower rate than therapies targeting other tissues [1,2].”
Experiments in medicalization: psychedelic therapy in Switzerland and Australia
Langlitz, N. (2025) · BioSocieties · doi:10.1057/s41292-025-00369-y · Cited by 6
Clinical pharmacology in neuroscience drug discovery: quo vadis?
Trist, D. G., Cohen, A. F., & Bye, A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.11.008 · Cited by 6
Prospects for neurodegenerative and psychiatric disorder drug discovery
Williams, M. J., & Enna, S. J. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.562497 · Cited by 6
“A major hurdle to drug discovery and development, this lack of predictability has contributed to a declining interest in this therapeutic area on the part of the pharmaceutical industry [12,13].”
Background
Industry withdrawal from psychiatric medication development
Klein, D. F., & Glick, I. D. (2014) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2014-3603 · Cited by 5
All levels of the translational spectrum must be targeted to advance psychopharmacology and improve patient outcomes
Yatham, L. N. (2023) · World Psychiatry · doi:10.1002/wps.21060 · Cited by 5
Building bridges between neuroscientific evidence and policy
Quaglio, G., McGuinness, M., Rübig, P., Nutt, D., Karapiperis, T., Pandolfo, M., & Südhof, T. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70014-1 · Cited by 6
Towards human central nervous system in vitromodels for preclinical research: strategies for 3D neural cell culture
Simão, D. F., Costa, I., Serra, M., et al. (2011) · BMC Proceedings · doi:10.1186/1753-6561-5-s8-p53 · Cited by 5
“However, those models often diverge considerably from that of human phenotype (anatomical, developmental and biochemical differences) [1] contributing to a high attrition rate - only 8% of CNS drugs entering clinical trials end up being approved [2].”
Background
Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development
Loïodice, S., Denibaud, A.-S., Deffains, W., Alix, M., Montagne, P., Seffals, M., & Rochelle, C. D. L. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00426 · Cited by 5
Clinical Trials in Psychiatry and Clinical Psychology: Science or Product Testing?
Woolfolk, R. L. (2015) · Acta Psychopathologica · doi:10.4172/2469-6676.100012 · Cited by 5
Real-Time fMRI in the Treatment of Mental Health DisordersPreprint
Taschereau‐Dumouchel, V., Cushing, C. A., & Lau, H. C. (2022) · doi:10.31234/osf.io/kxezs · Cited by 5
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4242829/v1 · Cited by 5
Psilocin fosters neuroplasticity in iPSC-derived human cortical neuronsPreprint
Schmidt, M., Hoffrichter, A., Davoudi, M., Horschitz, S., Lau, T., Meinhardt, M. W., Spanagel, R., Ladewig, J., Köhr, G., & Koch, P. (2025) · eLife · doi:10.7554/elife.104006 · Cited by 5
“Particularly, in times where the development and the approval of new medications is decreasing and the number of patients suffering from psychiatric disorders is rising, there is a huge need for new therapeutic interventions ( Miller, 2010 ; Schenberg, 2018 ).”
Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676
Varnäs, K., Juréus, A., Johnström, P., Ahlgren, C., Schött, P. A., Schou, M., Gruber, S. H. M., Jerning, E., Malmborg, J., Halldin, C., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.234146 · Cited by 4
“Introduction Discovery and development of drugs for diseases of the central nervous system (CNS) represent a major challenge to the pharmaceutic industry, with a higher rate of attrition than for other therapeutic areas (Kola and Landis, 2004; Miller, 2010).”
Background
Antidepressants: past, present and future
Stein, D. J. (2012) · doi:10.2217/ebo.11.394 · Cited by 5
Selective-serotonin reuptake inhibitors
Wang, L. L., & Lam, R. W. M. (2012) · doi:10.2217/ebo.11.385 · Cited by 5
Breaking Barriers: Advancements in CNS Drug Delivery for Glioblastoma
Fidawi, N. A., Attieh, C. Z., Baghdadi, L., et al. (2026) · Medical Sciences · doi:10.3390/medsci14010073 · Cited by 3
Development of an in vitro model of the neurovascular unit for BBB permeability-linked neuroactivity screening
Lubin, K. E., Xu, Z., Sluka, J. P., et al. (2024) · Medicinal Chemistry Research · doi:10.1007/s00044-024-03290-4 · Cited by 3
“Presently, there are few therapeutic agents for many neurological disorders such as neurodegenerative and neurodevelopmental diseases and mental illness [49].”
A novel in silico approach for predicting unbound brain-to-plasma ratio using machine learning-based support vector regression
Ta, G. H., & Leong, M. K. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110366 · Cited by 3
Can proteomics‐based diagnostics aid clinical psychiatry?
Filiou, M. D. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400144 · Cited by 3
National Institute of Mental Health Support for Cognitive Treatment Development in Schizophrenia: A Narrative Review
HEINSSEN, R. K., Morris, S. E., & Sherrill, J. T. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae109 · Cited by 4
Restoring trust in the pharmaceutical sector on the basis of the SSRI case
Hernandez, J. F., van Thiel, G. J. M. W., Mantel-Teeuwisse, A. K., Raaijmakers, J. A. M., & Pieters, T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.019 · Cited by 3
Analysis of Neuropsychiatric Disease‐Related Functional Neuroanatomical Markers in Mice
Garrett, L., Ung, M., Heermann, T., Niedermeier, K. M., & Hölter, S. M. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.37 · Cited by 3
“Furthermore, the pharmaceutical industry is investing less in psychiatric disease research due to lower clinical success rates of drugs (Miller, 2010).”
Background
NINDS Translational Programs: Priming the Pump of Neurotherapeutics Discovery and Development
Ranganathan, R. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.026 · Cited by 3
Unique Challenges in The Development of Therapies for Neurological Disorders
O’Neill, G. N. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139032445.004 · Cited by 3
Glück in der Psychopharmakologie. Affektives und kognitives Enhancement
Schleim, S. (2011) · J.B. Metzler eBooks · doi:10.1007/978-3-476-00372-0_71 · Cited by 3
Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?
Goldberg, J. F., & Rush, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363178 · Cited by 3
Possible directions for the discovery of new antidepressant
Young, S. N. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100169 · Cited by 2
“The situ ation is serious enough that GlaxoSmithKline and Astra Zeneca have decreased work in many areas of psychiatry, and a recent article in Science asks, “Is pharma running out of brainy ideas?”.(2) One of the problems is a lack of any clear understanding of the etiology of depression.”
Background
Medication Development: Reducing Casualties in the Valley of Death and Providing Support for Survivors
Aubin, H., & Mann, K. F. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13909 · Cited by 2
Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration
Gopalakrishnan, M., Farchione, T. R., Mathis, M. V., et al. (2020) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20200003 · Cited by 2
“Despite the growing economic and societal burden, the global pharmaceutical industry has significantly decreased its investment in new treatments for schizophrenia in recent years (2, 3).”
Consciousness, the affectome, and human life
LeDoux, J. E. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105601 · Cited by 2
Validity Drifts in Psychiatric Research
Michel, M. (2024) · The British Journal for the Philosophy of Science · doi:10.1086/730534 · Cited by 3
Predicting individual treatment response in alcohol use disorders: a reverse translational proof-of-concept study
Carlo, S. D., Mrizak, H., Valle, A. D., Lunerti, V., Kyratzi, M. O., Mammone, A., Lacorte, A., Keshishian, A., Li, M., Domi, E., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03431-2 · Cited by 3
“These failures brought despondency in professionals working in the ﬁ eld of psychiatric disorders in general, and of addiction in particular, and led major pharmaceutical companies to abandon drug research and development (R&D) in this ﬁ eld as it is perceived as at high risk of business [12].”
Comments on the working group’s 2012 review of the Program
Bialer, M. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03682.x · Cited by 2
Games for the Brain
Sahakian, B. J., d’Angelo, L.-S. C., & Savulich, G. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108565738.007 · Cited by 2

Authors: Miller, G.
Corresponding author: Miller, Greg
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2010-07-30
Volume: 329
Issue: 5991
Pages: 502-504
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.329.5991.502
OpenAlex: W2075757880
Cited by: 284
References: 0
Citations by year: 2026: 8 · 2025: 9 · 2024: 13 · 2023: 11 · 2022: 24 · 2021: 14 · 2020: 12 · 2019: 23 · 2018: 15 · 2017: 25 · 2016: 11 · 2015: 25 · 2014: 18 · 2013: 21 · 2012: 31
Type: other
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: drug development, neurological disorders, pharmaceutical industry, research funding cuts, brain research, neuropharmacology
MeSH terms: Mental Disorders, Central Nervous System Agents, Central Nervous System Diseases, Clinical Trials as Topic, Drug Industry, Humans, Drug Approval, Access to Information, Biomedical Research, Drug Discovery, Public-Private Sector Partnerships

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Is Pharma Running Out of Brainy Ideas?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks